---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-056469"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-02T23:55:27.964320+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cyclacel raises $8M in private placement of common stock and warrants

## Summary
- Sold 4,968,945 shares (or pre-funded warrants) plus series A/B warrants at $1.61 per unit; gross proceeds ~$8.0M.
- Series A warrants exercisable at $1.36 for 5.5 years; series B warrants for 18 months.
- H.C. Wainwright acted as placement agent; fees 7% cash plus 1% management fee and placement agent warrants.
- Net proceeds intended for working capital and general corporate purposes.

## SEC filing metadata
- accession: 0001104659-24-056469
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000110465924056469/0001104659-24-056469-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000110465924056469/tm2413298d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-056469
- JSON: https://secwatch.observer/filing/0001104659-24-056469.json
- Plain text: https://secwatch.observer/filing/0001104659-24-056469.txt

## Key facts
- Material Agreements
  Bio Green Med Solution, Inc. entered into Purchase Agreement with an institutional investor valued at approximately $8.0 million (effective 2024-04-30).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an institutional investor
  - Value: approximately $8.0 million
  - Effective: 2024-04-30
  source text: On April 30, 2024, Cyclacel Pharmaceuticals, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with an institutional investor (the “ Purchaser ”) for the issuance and sale in a private placement (the “ Private Placement ”) of (i) 145,000 shares of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000110465924056469/0001104659-24-056469-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.